Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | ELOC | Q15369 | 8/20 | 0.35 |
| ▸ | ELOB | Q15370 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8002433 | 0.90 | VHL (0.40) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL13703334 | 0.89 | VHL (0.40) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL15325938 | 0.88 | ALDH1A1 (0.39) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL20120873 | 0.82 | ELANE (0.44) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL8015855 | 0.82 | ELANE (0.44) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL20120875 | 0.82 | ELANE (0.44) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL806128 | 0.82 | ELANE (0.44) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL10292790 | 0.82 | ELANE (0.44) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL13318866 | 0.82 | ELANE (0.44) | VHLALDH1A1MMP2ANPEPPEPD | |
| SCHEMBL8253158 | 0.82 | ELANE (0.44) | VHLALDH1A1MMP2ANPEPPEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009117594-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, SPINT2, CTSV | VHL 948/4885ALDH1A1 707/4885CYP19A1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.